aileron
therapeutics
announces
data
featured
presentation
annual
symposium
aileron
aims
create
new
paradigm
proactive
prevention
side
effects
address
significant
unmet
need
among
cancer
patients
first
chemoprotective
therapy
clinical
development
utilize
biomarker
strategy
treating
patients
cancers
novel
mechanism
action
activates
selectively
shield
healthy
cells
chemotherapy
without
interrupting
chemotherapy
targeting
cancer
cells
company
hold
investor
call
monday
october
discuss
new
data
outline
strategy
advance
chemoprotection
across
multiple
cancers
chemotherapies
watertown
globe
newswire
aileron
therapeutics
nasdaq
alrn
today
announced
data
company
phase
study
featured
poster
presentation
annual
ena
symposium
molecular
targets
cancer
therapeutics
held
virtually
october
abstract
entitled
prevention
myelosuppression
sclc
patients
treated
dual
mdmx
inhibitor
presented
starting
saturday
october
ena
website
data
presented
aileron
phase
study
evaluating
therapeutic
agent
administered
ahead
chemotherapy
prevent
toxicities
severe
anemia
neutropenia
thrombocytopenia
patients
small
cell
lung
cancer
sclc
treated
chemotherapy
topotecan
june
aileron
announced
positive
interim
data
study
chemotherapy
remains
backbone
treatment
millions
cancer
patients
associated
toxicities
side
effects
ranging
unpleasant
sometimes
fatal
current
supportive
care
drugs
try
manage
side
effects
often
unsuccessfully
associated
toxicities
aileron
potential
bring
innovation
area
cancer
care
improving
patients
quality
life
well
tolerance
chemotherapy
said
manuel
aivado
president
chief
executive
officer
aileron
therapeutics
aivado
continued
first
chemoprotective
agent
utilize
biomarker
strategy
treating
patients
cancers
patients
designed
selectively
shield
healthy
cells
chemotherapy
continue
targeting
cancer
cells
believe
novel
mechanism
action
potential
introduce
transformative
paradigm
proactive
prevention
hematological
side
effects
importantly
approach
designed
give
oncologists
access
chemoprotective
agent
reduce
efficacy
aileron
vision
bring
chemoprotection
patients
cancers
represent
least
cancer
patients
regardless
cancer
type
chemotherapy
aileron
investor
call
aileron
host
virtual
investor
call
webcast
discuss
new
data
well
company
clinical
development
strategy
expand
chemoprotection
patients
cancers
event
take
place
monday
october
et
details
provided
closer
event
https
works
protect
healthy
cells
chemotherapy
developed
aileron
novel
chemoprotective
medicine
selectively
protect
healthy
cells
patients
cancers
harbor
reduce
eliminate
side
effects
chemotherapy
preferentially
acts
cells
cycling
undergoing
process
cell
division
cancer
cells
cell
cycle
unchecked
leads
uncontrolled
cell
proliferation
hallmark
cancer
certain
types
healthy
cells
also
naturally
need
cycle
bone
marrow
cells
hair
follicle
cells
skin
cells
cells
lining
oral
cavity
gastrointestinal
tract
result
chemotherapy
targets
kills
cycling
healthy
cells
cycling
cancer
cells
turn
leads
spectrum
side
effects
unpleasant
fatal
investigational
mdmx
dual
inhibitor
administered
prior
chemotherapy
patients
cancers
designed
activate
normal
protein
patients
healthy
cells
temporarily
reversibly
pausing
cell
cycling
selectively
shield
patients
healthy
cells
chemotherapy
protection
limited
healthy
cells
work
cancer
cells
given
lost
function
cells
therefore
cancer
cells
continue
cycle
uninterrupted
remain
fully
susceptible
destruction
chemotherapy
aileron
therapeutics
aileron
focused
transforming
experience
chemotherapy
cancer
patients
enabling
fight
cancer
without
fear
burden
side
effects
mdmx
dual
inhibitor
activating
therapeutic
agent
development
employ
biomarker
strategy
elicit
selective
chemoprotection
cancer
patients
unique
targeted
strategy
designed
protect
multiple
healthy
cell
types
throughout
body
chemotherapy
ensuring
chemotherapy
continues
destroy
cancer
cells
addition
potentially
reducing
eliminating
multiple
side
effects
may
also
improve
patients
quality
life
help
better
tolerate
chemotherapy
potentially
allowing
patients
complete
treatment
without
dose
reductions
delays
vision
bring
chemoprotection
patients
cancers
approximately
cancer
patients
regardless
cancer
type
chemotherapy
visit
us
learn
statements
statements
press
release
aileron
future
expectations
plans
prospects
well
statements
regarding
matters
historical
facts
may
constitute
statements
within
meaning
private
securities
litigation
reform
act
statements
include
limited
statements
company
strategy
clinical
development
plans
words
anticipate
believe
continue
could
estimate
expect
intend
may
plan
potential
predict
project
target
would
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
actual
results
may
differ
materially
indicated
statements
result
various
important
factors
including
whether
aileron
cash
resources
sufficient
fund
continuing
operations
periods
trials
anticipated
whether
results
obtained
preclinical
nonclinical
studies
clinical
trials
indicative
results
obtained
future
clinical
trials
whether
aileron
product
candidates
advance
clinical
trial
process
timely
basis
whether
results
trials
warrant
submission
approval
united
states
food
drug
administration
equivalent
foreign
regulatory
agencies
whether
aileron
product
candidates
receive
approval
regulatory
agencies
timely
basis
whether
product
candidates
obtain
approval
successfully
distributed
marketed
impact
coronavirus
pandemic
may
timing
clinical
development
clinical
supply
operations
factors
discussed
risk
factors
section
aileron
quarterly
report
form
period
ended
june
filed
august
risks
described
filings
aileron
may
make
securities
exchange
commission
statements
contained
press
release
speak
date
hereof
aileron
specifically
disclaims
obligation
update
statement
whether
new
information
future
events
otherwise
